Therapy Areas: Inflammatory Diseases
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...
Synlogic and Caldera Therapeutics agree merger
29 July 2026 - Biopharmaceutical company Synlogic Inc (OTC:SYBX) and Caldera Therapeutics Inc, a privately held clinical-stage biotechnology company announced on Wednesday that they have entered into ...
Harbour BioMed and Sinopharm establish innovation R&D consortium
27 July 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) declared on Monday that it has entered into a strategic collaboration with China National Pharmaceutical Group Co Ltd (Sinopharm) ...
Zoetis introduces Portela for feline osteoarthritis pain relief in Canada and EU
22 July 2026 - Animal health company Zoetis Inc (NYSE: ZTS) announced on Wednesday that it has launched Portela (relfovetmab) in Canada and European Union member states, introducing the first long-act...
Arch Biopartners engages private lab to advance IL-32 chronic kidney disease programme
20 July 2026 - Canada-based biotechnology company Arch Biopartners Inc (TSX-V:ARCH) (OTCQB:ACHFF) announced on Friday that it has engaged a US-based laboratory specialising in bioengineering to accele...
Vanda Pharmaceuticals reports positive EMA opinion on orphan drug designation for imsidolimab in generalised pustular psoriasis
17 July 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Thursday that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopt...